# Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

> **NCT05762211** · PHASE2 · RECRUITING · sponsor: **MaaT Pharma** · enrollment: 387 (estimated)

## Conditions studied

- Transplant Complication

## Interventions

- **DRUG:** Pooled allogeneic fecal microbiotherapy
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05762211
- **Lead sponsor:** MaaT Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-31
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-02-15
- **Target enrollment:** 387 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05762211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05762211, "Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05762211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*